Metabolism and the Activity of the Autonomic Nervous System in Patients With Paroxystic Sympathetic Hyperactivity, PSH (MANS-PSH)
Adult patients suffering from acquired brain damage run the risk of developing PSH. This group of patients is admitted to our unit, the Neurointensive Stepdown Unit, at Silkeborg Regional Hospital for intensive care and early neurorehabilitation. After weaning from intensive carethey are transferred to Hammel NeuroCentre.
Aim is to assess whether HRV-derived variables in the frequency domain mirror therapeutic and/or nursing and/or pharmacologic interventions. To the extent clinically available BRS and metabolism are included in the assessment.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
See report:
Honore H, Eggertsen K, Sondergaard S: A study into the feasibility of using HRV variables to guide treatment in patients with paroxystic sympathetic hyperactivity in a neurointensive step-down unit. NeuroRehabilitation 2019, 44(1):141-155.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Symptoms of PSH according to Baguley scoring table
Exclusion Criteria:
No symptoms of PSH
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference before vs after intervention in frequency domain parameters of HRV
Time Frame: immediate
|
HRV parameters: low frequency (LF, 0.04-0.15
Hz), high frequency (HF, 0.15-0.4
Hz) in terms of peak frequency (Hz), absolute power (ms2, natural logarithm transformed values of absolute powers of VLF, LF, and HF bands), relative power (absolute power/total power), normalized power (%, normalized units, n.u.), total power given by VLF + HF + LF (ms2) and LF/HF ratio.
|
immediate
|
|
Qualitative description expressed as goal attainment scaling (GAS) of therapeutic interventions
Time Frame: immediate
|
Two independent ratings on a 5-point scale, -2 to +2
|
immediate
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jørgen Feldbæk, Professor, Hammel Neuro- and Research Centre
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 654865
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autonomic Nervous System Imbalance
-
NCT06542510CompletedAutonomic Nervous System Imbalance
-
NCT03613961CompletedAutonomic Nervous System Imbalance
-
NCT06730165CompletedAutonomic Nervous System Imbalance
-
NCT05906940CompletedAutonomic Nervous System Imbalance
-
NCT03888456CompletedHealthy | Autonomic Nervous System Imbalance
-
NCT04100486Enrolling by invitationAutonomic Nervous System Diseases | Autonomic Dysfunction | Autonomic Imbalance | Vagus Nerve Autonomic Disorder
-
NCT03302923UnknownPhysical Activity | Autonomic Nervous System Imbalance
-
NCT07330700CompletedType2 Diabetes Mellitus | Autonomic Nervous System Imbalance
Clinical Trials on Physio-/occupational therapy
-
NCT05699031RecruitingSHOULDER ARTHROPLASTY | REHABILITATION | TELEREHABILITATION
-
NCT03723863TerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIc
-
NCT02442622Completedde Quervain's Disease
-
NCT02906306CompletedWell-being | Individuality | Self-Efficacy
-
NCT06484946CompletedADHD | Autism Spectrum Disorder | Sensory Processing Disorder
-
NCT07283211CompletedCerebral Palsy (CP) | Activities of Daily Living
-
NCT05199987CompletedSevere Chronic Obstructive Pulmonary Disease
-
NCT04465422CompletedOccupational Therapy | Psychiatric Rehabilitation
-
NCT03957993CompletedAutism Spectrum Disorder | Attention Deficit Hyperactivity Disorder